Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration | Acta Neuropsychiatrica

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Ibogaine is a psychedelic alkaloid without an approved indication. Observational clinical research shows linkages between single administration of ibogaine and relief of symptoms of neuropsychiatric conditions including substance use disorder, multiple sclerosis, and traumatic brain injury. Ibogaine has multi-receptor actions, but the ...

Continue Reading →

Access Denied


Access Denied

You don’t have permission to access “http://www.dallasnews.com/arts-entertainment/lifestyle/2026/02/11/texas-is-funding-research-into-the-psychedelic-ibogaine-heres-what-to-know/” on this server.

Reference #18.c55c4f68.1770842529.30447621

https://errors.edgesuite.net/18.c55c4f68.1770842529.30447621

Source link

Continue Reading →
Bradley Arant Boult Cummings LLP

I Can See Clearly Now the Rain Is Gone: As Major Legislative Deadline Passes, New Laws Governing Mississippi Cannabis and Potential Ibogaine Clinical Trials Emerge | Bradley Arant Boult Cummings LLP

As the frozen precipitation is continuing to thaw across the upper part of Mississippi, the Mississippi legislature continues to forge ahead in this year’s legislative session. If you tuned into the webinar we hosted on January 14, you heard our Mississippi government affairs colleague, Spencer Ritchie, discuss the cannabis-related legislation he expected to see this legislative session. Now one month into the session and shortly after the deadline for bills to make ...

Continue Reading →
Page 6 of 110 «...45678...»
UA-77446339-1